FATE Historical PE Ratio Notes

— Fate Therapeutics (ticker: FATE) is a biotechnology company focused on developing cellular immunotherapies—particularly using natural killer (NK) cells & T cells—for cancer and immune disorders. The company leverages proprietary induced pluripotent stem cell (iPSC) technology to create off-the-shelf, engineered cell treatments. Given its emphasis on cutting-edge drug development, Fate has historically generated little to no revenue, instead investing heavily in research & development. As a result, its reported earnings have been negative or minimal for most periods, often leading to undefined or extremely high price-to-earnings (PE) ratios in historical charts & tables. For biotechs like Fate that are in pre-commercial stages or early clinical trials, historical PE ratios typically reflect investor optimism about future breakthroughs, rather than current profitability. When reviewing Fate's historical price, earnings, & PE ratio data, it’s important to understand that fluctuations are primarily driven by advancements in clinical development, regulatory milestones, & market sentiment about long-term potential—not stable earnings. Thus, PE ratio trends for Fate may be volatile, irregular, or not meaningful in some periods, which can differ significantly from established companies in mature industries.

On this page we presented the Fate Therapeutics Historical PE Ratio information for Fate Therapeutics' stock. The average FATE historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average FATE historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this FATE historical PE result, against the recent PE: when this page was posted on 5/15/2026, the most recent closing price for FATE had been 1.76, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on FATE or any other given stock, valuation analysis for FATE can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Fate Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for FATE. Thanks for visiting, and the next time you need to research FATE Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.